BioPharmSignal logoBioPharmSignal

Biotech News

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

TG Therapeutics (TGTX)TG TherapeuticsConference / presentation

Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C.

Related news

TGTXTG Therapeutics2026-09-03 11:30 EST

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

TGTXTG Therapeutics2026-06-02 11:30 EST

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

View all latest news

TG Therapeutics

B-Cell-Directed Therapies TG Therapeutics develops and commercializes therapies targeting B cells in multiple sclerosis and other autoimmune diseases. Its portfolio combines an approved anti-CD20 antibody with alternative formulations and an allogeneic cell-therapy program. BRIUMVI BRIUMVI, or ublituximab, is a glycoengineered CD20...

Recent company news

TGTXTG Therapeutics2026-09-10 11:30 EST

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

TGTXTG Therapeutics2026-09-03 11:30 EST

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

TGTXTG Therapeutics2026-08-03 11:00 EST

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TGTXTG Therapeutics2026-07-29 11:30 EST

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

TGTXTG Therapeutics2026-07-06 11:30 EST

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

Stock data

Close
53.62 USD
Market cap
5.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States